ImmunoGen, Inc. clinical trials
Acquired by AbbVie, Feb 12, 2024 · source ↗
The registry lists 16 studies whose lead sponsor is ImmunoGen, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 15, 2025.
Before and after it joined AbbVie
- First submitted before ImmunoGen, Inc. became part of AbbVie
- 16
- First submitted after ImmunoGen, Inc. became part of AbbVie
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- ImmunoGen, Inc.16 studies
Something wrong with this grouping? Tell us on the AbbVie page.
Studies
Recruiting first, then most recently updated. Showing 16 of 16. All AbbVie studies →
- First-in-Human Study of IMGC936 in Participants With Advanced Solid TumorsCompletedNCT04622774Phase 1/2
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionCompletedNCT04296890Phase 3
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02606305Phase 1/2
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid TumorsCompletedNCT01609556Phase 1
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube CancerCompletedNCT02631876Phase 3
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid LeukemiaCompletedNCT02674763Phase 1
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung CancerTerminatedNCT01237678Phase 1/2
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01534715Phase 1
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid TumorsTerminatedNCT01963715Phase 1
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction CarcinomasWithdrawnNCT00620607Phase 2
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- BB-10901 in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00346385Phase 1
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- IMGN901 in Combination With Lenalidomide and DexamethasoneCompletedNCT00991562Phase 1
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid TumorsCompletedNCT00721669Phase 1
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT00346255Phase 1
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung CancerCompletedNCT00065429Phase 1/2
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie
- Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid TumorsCompletedNCT00352131Phase 1
Sponsor listed in the registry: ImmunoGen, Inc. · First submitted before ImmunoGen, Inc. became part of AbbVie